Key result
Ranolazine significantly reduced mean daily step count by 837 steps compared to placebo in patients with coronary microvascular dysfunction.
Why the study?
Does ranolazine improve daily step count measured by wearable technology in patients with angina and coronary microvascular dysfunction?
RCT (n=30)
Double-blind
1:1
Yes
Does ranolazine improve daily step count measured by wearable technology in patients with angina and coronary microvascular dysfunction?
Effect estimate: Mean difference -836.8 (95% CI -1464.74 to -208.86)
Absolute Event Rate: 5756.49% vs 6593.29%
p-value: p=0.01
In patients with coronary microvascular dysfunction, ranolazine paradoxically decreased overall daily step counts compared to placebo, though step counts increased in the subgroup that experienced angina improvement.
No takes yet. Share an insight, caveat, or question.
Ranolazine reduces daily activity in coronary microvascular dysfunction; challenges assumptions of benefit and warrants caution in this population.
Birkeland et al. (2017) conducted an RCT in Coronary microvascular dysfunction with angina and no obstructive coronary artery disease (n=30). Ranolazine vs. Placebo was evaluated on Mean daily step count (Mean difference -836.8, 95% CI -1464.74 to -208.86, p=0.01). Ranolazine significantly reduced mean daily step count by 837 steps compared to placebo in patients with coronary microvascular dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: